Consequences of long-term hormone replacement therapy

被引:14
作者
Purdie, DW [1 ]
机构
[1] Hull Royal Infirm, Ctr Metab Bone Dis, Hull HU3 2RW, N Humberside, England
关键词
D O I
10.1258/0007142001903382
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The use of oestrogens in the longer term is an area of considerable current scientific and clinical debate. The extra-reproductive range of oestrogen actions is broad, with these steroid hormones and their receptors (ERs) being intimately involved in the normal function of, inter alia, the adult female skeleton, the cardiovascular system and the brain. Desirable as the restoration of normal circulating oestrogen may be after menopause, HRT use is compromised by the engagement of the reproductive sites of breast and uterus. This may cause concern to patient and physician alike due to the consequent imposition of cyclical bleeding and risk of breast malignancy. In the individual patient, therefore, a balance of risk against benefit has to be struck so that the patient may be precisely advised of the type and duration of oestrogen replacement which may be indicated in her own case. The advent of selective oestrogen receptor modulation with its ability to delete adverse effects in breast and endometrium, is a substantial pharmacological and clinical advance.
引用
收藏
页码:809 / 823
页数:15
相关论文
共 61 条
[1]   Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism [J].
Albright, F ;
Burnett, CH ;
Cope, O ;
Parson, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY, 1941, 1 (09) :711-716
[2]  
Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
[3]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[4]   TREATMENT OF OSTEOPOROSIS WITH PARATHYROID PEPTIDE (HPTH 1-34) AND ESTROGEN - INCREASE IN VOLUMETRIC DENSITY OF ILIAC CANCELLOUS BONE MAY DEPEND ON REDUCED TRABECULAR SPACING AS WELL AS INCREASED THICKNESS OF PACKETS OF NEWLY FORMED BONE [J].
BRADBEER, JN ;
ARLOT, ME ;
MEUNIER, PJ ;
REEVE, J .
CLINICAL ENDOCRINOLOGY, 1992, 37 (03) :282-289
[5]   Evidence for plasma membrane-mediated effects of estrogen [J].
Brubaker, KD ;
Gay, CV .
CALCIFIED TISSUE INTERNATIONAL, 1999, 64 (06) :459-462
[6]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[7]  
CAULEY JA, 1994, ANN INTERN MED, V122, P9
[8]   ESTROGEN-RECEPTORS IN HUMAN NONTARGET TISSUES - BIOLOGICAL AND CLINICAL IMPLICATIONS [J].
CIOCCA, DR ;
ROIG, LMV .
ENDOCRINE REVIEWS, 1995, 16 (01) :35-62
[9]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[10]   Risk of venous thromboembolism in users of hormone replacement therapy [J].
Daly, E ;
Vessey, MP ;
Hawkins, MN ;
Carson, JL ;
Gough, P ;
Marsh, S .
LANCET, 1996, 348 (9033) :977-980